848070-26-8 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule of the compound.
Explanation
It is a compound formed by the reaction of an acid (in this case, piperidinetricarboxylic acid) with an alcohol, resulting in the formation of an ester.
Explanation
The appearance of the compound, which can range from colorless to a light yellow hue.
Explanation
The compound has a very mild or barely noticeable smell.
Explanation
The compound exists in a liquid state at room temperature.
Explanation
The compound has a high boiling point, which means it requires a significant amount of heat to change from a liquid to a gas.
Explanation
The compound has low vapor pressure, indicating that it does not easily evaporate or transition from a liquid to a gas at room temperature.
Explanation
The compound is stable, meaning it does not readily undergo chemical reactions or break down under normal conditions.
Explanation
The compound is used as an intermediate in the production of various drugs and agricultural products, contributing to its wide range of applications in the chemical industry.
Ester derivative
of piperidinetricarboxylic acid
Color
Colorless to pale yellow
Odor
Faint
Physical state
Liquid
Boiling point
High
Vapor pressure
Low
Stability
Stable
Applications
Pharmaceutical and agrochemical synthesis
Check Digit Verification of cas no
The CAS Registry Mumber 848070-26-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,8,0,7 and 0 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 848070-26:
(8*8)+(7*4)+(6*8)+(5*0)+(4*7)+(3*0)+(2*2)+(1*6)=178
178 % 10 = 8
So 848070-26-8 is a valid CAS Registry Number.
848070-26-8Relevant articles and documents
NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF
-
Page/Page column 121, (2018/12/13)
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.
An improved synthesis of 2-oxa-7-azaspiro[3,5]nonane and analogs as novel reagents in medicinal chemistry
Xu, Ruo,Czarniecki, Michael,Man, Jos De,Pan, Jianping,Qiang, Li,Root, Yuriko,Ying, Shihong,Su, Jing,Sun, Xijun,Zhang, Yuping,Yu, Tao,Zhang, Yang,Hu, Tao,Chen, Shu-Hui
experimental part, p. 3266 - 3270 (2011/07/08)
A detailed synthesis of novel spirocyclic oxetane analogs is described for the first time.
QUINOLONE ANTIBACTERIAL AGENTS
-
Page/Page column 114, (2010/02/11)
Compounds of formula (I, II, III, IV, V, and VI) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compounds of formula (I) as disclosed herein can be used in a variety of applications including use as antibacterial agents.